Kyowa Hakko Kogyo Co., Ltd. licenses its in-house developed antibody KW-2871 targeting malignant melanoma to Life Science Pharma
Kyowa Hakko Kogyo Co., Ltd. (KHK) agreed to license its in-house developed antibody KW-2871 to US pharmaceutical development company Life Science Pharmaceuticals (LSP). KHK grants to LSP an exclusive world-wide license to develop and market the compound. KW-2871 will be continued to be developed by the Ludwig Institute for Cancer Research (LICR) based in New York in collaboration with LSP. The compound entered Phase I/IIa clinical trials targeting a skin cancer, malignant melanoma, in 2002 in the US. After their completion, an additional study has been conducted to find the optimal dose.
Under this agreement, KHK will receive an upfront payment, milestone payments and royalties on sales of commercialized products from LSP.
KW-2871 is a chimeric monoclonal antibody specifically binding to the ganglioside antigen, GD3, expressed on the surface of malignant melanoma cells and exerts an anticancer effect by activating effector cells (natural killer cells, monocytes, etc.) which kill, mediated by antibodies, the target cells including cancer cells (antibody-dependent cellular cytotoxicity, ADCC), or destroying cell membranes with complement proteins (complement-dependent cytotoxicity).
Other news from the department science
These products might interest you
Hydrosart® Ultrafilter by Sartorius
Efficient ultrafiltration for biotech and pharma
Maximum flow rates and minimum protein loss with Hydrosart® membranes
Hydrosart® Microfilter by Sartorius
Hydrophilic microfilters for bioprocesses
Minimal protein adsorption and high flow rates
Sartobind® Rapid A by Sartorius
Efficient chromatography with disposable membranes
Increase productivity and reduce costs with fast cycle times
Sartopore® Platinum by Sartorius
Efficient filtration with minimal protein adsorption
Reduces rinsing volume by 95 % and offers 1 m² filtration area per 10"
Polyethersulfone Ultrafilter by Sartorius
Reliable filtration with PESU membranes
Perfect for biotechnology and pharmaceuticals, withstands sterilisation and high temperatures
Polyethersulfone Microfilter by Sartorius
Biotechnological filtration made easy
Highly stable 0.1 µm PESU membranes for maximum efficiency
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
